Brian M. Culley, President and CEO of Lineage Cell Therapeutics, Inc. (NASDAQ:LCTX), filed a Form 4 on November 17, 2026, disclosing an open-market purchase of 40,500 common shares on November 16, 2026.

Key Highlights

  • Transaction date: November 16, 2026, with 40,500 common shares acquired (transaction code P).
  • Weighted average price: $0.916 per share, with individual transactions ranging from $0.85 to $1.00 inclusive.
  • Resulting ownership: Culley directly holds 296,016 common shares following the reported transaction.
  • Reporting person: Brian M. Culley, identified in the filing as President and CEO and as a Director of Lineage Cell Therapeutics.
  • Price detail available: The filing states that full information on shares purchased at each separate price within the range will be provided upon request to the issuer, any security holder, or SEC staff.

Brian M. Culley's November 2026 Open-Market Purchase of Lineage Common Shares

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Brian M. Culley, who serves as both President and CEO and as a Director of Lineage Cell Therapeutics, Inc., acquired 40,500 common shares on November 16, 2026. The filing identifies the transaction code as "P," indicating an open-market purchase. The reported price is a weighted average of $0.916 per share.

The filing notes that the 40,500 shares were purchased across multiple transactions at prices ranging from $0.85 to $1.00 per share, inclusive. The reporting person, according to the filing, "undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote." Following the transaction, Culley's direct beneficial ownership stands at 296,016 common shares, as reported in Table I of the filing.

No derivative securities transactions were reported. The filing was submitted by one reporting person, Culley himself, and covers only the single non-derivative transaction dated November 16, 2026. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) plan, as that checkbox was not selected on the form.

What Was Disclosed

Lineage Cell Therapeutics' President and CEO Brian M. Culley disclosed a direct purchase of 40,500 common shares at a weighted average price of $0.916, bringing his total direct beneficial ownership to 296,016 shares as of November 16, 2026.